Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer

MENG Wenjing; TONG Zhongsheng

doi:10.3971/j.issn.1000-8578.2023.22.0769

MENG Wenjing, TONG Zhongsheng. Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769

Citation:

MENG Wenjing, TONG Zhongsheng. Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769

Citation:

MENG Wenjing, TONG Zhongsheng. Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769

Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer

Abstract

Abstract

HER2 is a tyrosine kinase receptor. It is the main drug target and clinical biomarker for the treatment of breast cancer. About 2% of breast cancer cases has HER2 mutations. Regardless of the expression level or amplification status of HER2, breast cancer with HER2 mutations may respond to targeted HER2 therapy. This article reviews the research progress of HER2 gene mutation in the treatment of breast cancer.

FullText(HTML)

References (22)

Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer

Abstract

Catalog

Export File

Citation

Format

Content